Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew S Waitkus

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Neuro-Oncology|January 10, 2026
SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use Alternative Lengthening of TelomeresAlexandrea Brown, Laura M Strickland, Elise N Erman, et al.
Molecular Cancer Research : MCR|February 3, 2017
Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor ProgressionChristopher J Pirozzi, Austin B Carpenter, Matthew S Waitkus, et al.
Cancer Research|November 4, 2017
Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1<sup>R132H</sup>-Induced Metabolic LiabilitiesMatthew S Waitkus, Christopher J Pirozzi, Casey J Moure, et al.
Nature Communications|June 20, 2020
The integrated genomic and epigenomic landscape of brainstem gliomaLee H Chen, Changcun Pan, Bill H Diplas, et al.
Nature Communications|May 27, 2018
The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastomaBill H Diplas, Xujun He, Jacqueline A Brosnan-Cashman, et al.
Biorxiv : the Preprint Server for Biology|May 3, 2023
Interplay between <i>ATRX</i> and <i>IDH1</i> mutations governs innate immune responses in diffuse gliomasSeethalakshmi Hariharan, Benjamin T Whitfield, Christopher J Pirozzi, et al.
Nature Communications|January 25, 2024
Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomasSeethalakshmi Hariharan, Benjamin T Whitfield, Christopher J Pirozzi, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Neuro-Oncology|January 10, 2026
SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use Alternative Lengthening of TelomeresAlexandrea Brown, Laura M Strickland, Elise N Erman, et al.
Molecular Cancer Research : MCR|February 3, 2017
Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor ProgressionChristopher J Pirozzi, Austin B Carpenter, Matthew S Waitkus, et al.
Cancer Research|November 4, 2017
Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1<sup>R132H</sup>-Induced Metabolic LiabilitiesMatthew S Waitkus, Christopher J Pirozzi, Casey J Moure, et al.
Nature Communications|June 20, 2020
The integrated genomic and epigenomic landscape of brainstem gliomaLee H Chen, Changcun Pan, Bill H Diplas, et al.
Nature Communications|May 27, 2018
The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastomaBill H Diplas, Xujun He, Jacqueline A Brosnan-Cashman, et al.
Biorxiv : the Preprint Server for Biology|May 3, 2023
Interplay between <i>ATRX</i> and <i>IDH1</i> mutations governs innate immune responses in diffuse gliomasSeethalakshmi Hariharan, Benjamin T Whitfield, Christopher J Pirozzi, et al.
Nature Communications|January 25, 2024
Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomasSeethalakshmi Hariharan, Benjamin T Whitfield, Christopher J Pirozzi, et al.
Pageof 3